Change in Plaque Characteristics With Atorvastatin

Wakayama Medical University70 enrolled

Overview

To examine effects of intensive lipid lowering therapy with atorvastatin on stabilization of coronary plaque by using optical coherence tomography (OCT) in patients with acute coronary syndrome.

Patients with acute coronary syndrome (myocardial infarction or unstable angina) who will undergo PCI and have at least one atherosclerotic lesion of \>25% stenosis other than culprit lesions of current ACS are enrolled. Fibrous cap thickness of a target coronary plaque is evaluated by optical coherence tomography.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Acute Coronary Syndrome Atherosclerosis Dyslipidemia

Interventions

high-dose atorvastatinDRUG

20mg/day

low-dose atorvastatinDRUG

5mg/day

Eligibility

Sex: ALLMin age: 20 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with acute coronary syndrome (myocardial infarction or unstable angina) who will undergo PCI. * plasma LDL cholesterol levels : \>=100mg/dL and ≤160mg/dL * at least one atherosclerotic lesion of \>25% stenosis other than culprit lesions of current ACS Exclusion Criteria: * Patients who will undergo coronary bypass surgery. * Patients with major complications during treatment of culprit coronary lesions. * Patients with an atherosclerotic lesion with \>50% stenosis at a left main trunk.

Locations (1)

Wakayama Medical University

Wakayama, Wakayama, Japan

Outcomes

Primary Outcomes

Fibrous cap thickness by OCT

Time frame: 12 months

Secondary Outcomes

macrophage number

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.